Repligen | RGEN - 债务



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.28B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


债务 更改 日
Agilent USD 3.35B 0 2025-12
Align Technology USD 116.04M 1.6M 2026-03
Bio Techne USD 200M 0 2026-06
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Bruker USD 1.82B 153.5M 2026-06
Charles River Laboratories USD 3.06B 485.84M 2026-03
Danaher USD 26.56B 8.07B 2026-06
Dentsply International USD 2.33B 137M 2026-03
General Electric Aerospace USD 19.16B 1.12B 2026-06
Henry Schein USD 3.81B 64M 2026-06
Illumina USD 2.54B 9M 2026-03
IQVIA Holdings USD 16.24B 408M 2026-06
Mettler Toledo International USD 2.23B 76.47M 2026-03
Myriad Genetics USD 59.3M 19.7M 2025-03
OraSure Technologies USD 782K 465K 2024-06
Pacific Biosciences Of California USD 892.24M 653K 2023-12
Pfizer USD 63.19B 536M 2026-06
Repligen USD 690.94M 144.36M 2026-06
Revvity USD 3.35B 48.03M 2026-03
Standard Biotools USD 29.49M 2.1M 2026-03
Thermo Fisher Scientific USD 43.16B 3.78B 2026-03
Waters USD 5.57B 4.08B 2026-03
West Pharmaceutical Services USD 202.8M 0 2026-03